1. Home
  2. ABP vs EVAX Comparison

ABP vs EVAX Comparison

Compare ABP & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABP
  • EVAX
  • Stock Information
  • Founded
  • ABP 2004
  • EVAX 2008
  • Country
  • ABP United States
  • EVAX Denmark
  • Employees
  • ABP N/A
  • EVAX N/A
  • Industry
  • ABP Biotechnology: Pharmaceutical Preparations
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ABP Health Care
  • EVAX Health Care
  • Exchange
  • ABP Nasdaq
  • EVAX Nasdaq
  • Market Cap
  • ABP 17.2M
  • EVAX 17.8M
  • IPO Year
  • ABP N/A
  • EVAX 2021
  • Fundamental
  • Price
  • ABP $0.18
  • EVAX $2.94
  • Analyst Decision
  • ABP Strong Buy
  • EVAX Strong Buy
  • Analyst Count
  • ABP 1
  • EVAX 2
  • Target Price
  • ABP $4.00
  • EVAX $10.00
  • AVG Volume (30 Days)
  • ABP 3.2M
  • EVAX 89.3K
  • Earning Date
  • ABP 08-13-2025
  • EVAX 10-30-2025
  • Dividend Yield
  • ABP N/A
  • EVAX N/A
  • EPS Growth
  • ABP N/A
  • EVAX N/A
  • EPS
  • ABP N/A
  • EVAX N/A
  • Revenue
  • ABP $183,000.00
  • EVAX $3,176,000.00
  • Revenue This Year
  • ABP N/A
  • EVAX N/A
  • Revenue Next Year
  • ABP N/A
  • EVAX N/A
  • P/E Ratio
  • ABP N/A
  • EVAX N/A
  • Revenue Growth
  • ABP 154.17
  • EVAX 1042.45
  • 52 Week Low
  • ABP $0.15
  • EVAX $1.20
  • 52 Week High
  • ABP $11.19
  • EVAX $17.20
  • Technical
  • Relative Strength Index (RSI)
  • ABP 35.07
  • EVAX 52.59
  • Support Level
  • ABP $0.16
  • EVAX $2.71
  • Resistance Level
  • ABP $0.26
  • EVAX $3.04
  • Average True Range (ATR)
  • ABP 0.02
  • EVAX 0.19
  • MACD
  • ABP -0.01
  • EVAX -0.02
  • Stochastic Oscillator
  • ABP 19.90
  • EVAX 57.53

About ABP Abpro Holdings Inc Common Stock

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

Share on Social Networks: